



SEMPERIT GROUP FY 2020 INVESTOR PRESENTATION

Dr Martin Füllenbach, CEO

Gabriele Schalleger, CFO

18 March 2021



Agenda

Key Highlights (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)


Outlook (p.21)

Appendix (p.24)




Historical record results for Semperit


EBITDA




EBIT



NET PROFIT AFTER TAX



FREE CASH-FLOW



▶ Successful restructuring process of the Industrial Sector significantly improves operational profitability significantly despite the pandemic effects

▶ Bolstered by the overall higher operational performance and increased efficiency the tailwind of the corona pandemic boosts Sempermed results to an extraordinary level

▶ The year of corona pandemic spurred the initiation of a new cost reduction program to support future results

▶ € 1.50 dividend proposal to the AGM

Figures adjusted for one-off effects



Corona pandemic defines transition period



Medical Sector

- High price level supported by own efficiency measures led to record sales and margins



Industrial Sector

- New industrial rubber strategy defined in January 2020
- Industrial portfolio expanded into four segments leading to greater diversification


Supply chain disruption, bottlenecks for container availability and raw materials, prices on the rise

- Very **high global demand** for hygienic equipment
- Market **prices** have **tripled**
- Sales **volumes increased** on the back of significantly higher productivity (OEE improvement from approx. 65% in 2018 to >90% by the end of 2020)
- **Turnaround of operational efficiency** supports currently high demand with no visibility for immediate end to market rally
- Industrial segments face **lower demand** and reduced order books with **different speed in market recovery**
- **The market has recovered faster** than anticipated 4 months ago
- **Yellow goods** and **construction** industries show **strong momentum**
- Number of projects strongly increasing for Sempertrans
- Restructuring made **industrial segments** highly **resilient**
- Flexible time models enable optimised capacity utilisation

2018-20 restructuring turned Semperit into a more profitable, agile and sustainable company



Industrial strategy update

-  Semperit Industry aims for >EUR 1 bn sales and overall EBITDA margin >13% **with a balanced and sustainable portfolio** despite volatile industry environment
-  Based on an integrated and transparently developed Semperit **portfolio review** a set of strategic actions has been derived
-  Organic growth potential within the industrial segment needs to go along with a **strong inorganic M&A strategy to reach** the anticipated **target**
-  Semperit plans strategic M&A using a **multidimensional screening approach**



Identify winning industries by global megatrends



Define the proximity to the current value chain



Define criteria for the market attractiveness and competitive position



Long-term defensible technological value proposition



Agenda

Key Highlights (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)



Outlook (p.21)

Appendix (p.24)



We promised and delivered (1/2)

- Continuing exceptional performance of Medical Sector both at top line and profitability continues
- Industrial Sector: resilient margins despite the pressure on top line
- Operational Group EBITDA yoy improvement for 12th consecutive quarter



- **Revenue +10.4%**
 - Medical Sector at € 449.2m, up by +53.1%
 - Industrial Sector at € 478.4m, down by -12.6%
- **EBITDA at € 208.6m >100%**
- **EBIT at € 237.8m >100%**
 - positive impact on reported EBIT due to reversal of Sempermed impairment in Q2'20
 - At operational level: Adjusted EBIT six times higher yoy compared to 2019


1) 2019: adjusted for one-off effect due to release of provision in Sempermed for Brazilian court case for tax liabilities (€ 4m)
 2018: adjusted for one-off effect of € 4m from closure of Sempertrans site in China.
 2017: adjusted for one-off effects from JV transaction of € 85m and one-off effects from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m) and expenses resulting from tax audit in Austria (€ 5m)




We promised and delivered – Industrial Sector (2/2)

Resilient margin development due to restructuring and efficiency enhancement

Full year comparison '17-'20¹⁾



Quarterly development '18-'20



— adjusted FY EBITDA-margin in %

- EBITDA '18 in € m — EBITDA '18 margin in %
- EBITDA '19 in € m — EBITDA '19 margin in %
- EBITDA '20 in € m — EBITDA '20 margin in %


¹⁾ FY'17 adjusted by EUR 11m for the one-off effects from the shutdown of the Sempertrans production site in France and by EUR 3m for the expenses in the course of the Austrian tax audit; FY & Q2'18 EBITDA adjusted by € 4m due to closure of Sempertrans site in China.




Semperflex FY 2020

EBITDA under FY 2019 level – but margin remains high

Semperflex



FY 2020 vs. FY 2019



- Revenue down due to reduced market demand following the corona pandemic impact in FY 2020 and the global economic downturn since FY 2019
- Size of order book down yoy, but trend change in Q4 to improved order intake
- EBITDA in FY 2020 below FY 2019 (-12.6%)







Sempertrans FY 2020

Severe external pressure on the business

Sempertrans



FY 2020 vs. FY 2019



- Sales were particularly impacted by corona in 2020
- Global mining companies were largely forced to stop operations
- Large capex reductions reflected in drop of order intake especially in H2'20
- Operational results maintained at a solid level compared to 2019 (7.7% vs 10.1% EBITDA margin)
- Impairment in H1'20 triggered by consistently negative market impact from corona burdens reported EBIT²⁾



1) Q1'19 Revenue and EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China



2) Impairment requirement recognised at the end of the second quarter, now amounting to EUR 19.8 million based on average 2020 foreign exchange rates for 2020




Sempersal FY 2020

Margins kept above last year's level despite corona

Sempersal



FY 2020 vs. FY 2019



- Different industries recovered at different speed, in particular the construction industry
- Order book above Q4'19 due to better customer intimacy, with strong customer feedback
- While EBITDA increased by 5.6% yoy, EBITDA margin at 11.8% even above last year due to stringent operational restructuring
- Acquisition of M&R Dichtungstechnik in Q4'20, a leading company in individual facades





Split of former Semperform into Sempersal and Semperform as of 1st January 2020




Semperform FY 2020

Margins exceeding 2019 level


Semperform



FY 2020 vs. FY 2019



- Semperform managed to defend its market share despite economic recession and Corona pandemic
- Demand in our focus industries started to pick up again in H2 despite some sectors (e.g. ski-tourism) currently operating at a much lower level
- FY 2020 margin up by 1.2PP yoy due to a better product mix and substantial operational savings
- Staying (virtually) close to the customers paid off: the average share-of-wallet increased



Split of former Semperform into Semperseal and Semperform as of 1st January 2020 – historic Semperform numbers adjusted accordingly




Medical Sector / Sempermed segment FY 2020


EBITDA margin boosted by market dynamics, leveraged by operational efficiency

Medical Sector

Sempermed



FY 2020 vs. FY 2019



- Strong top line growth driven by high demand and increasing market prices supported by very high production output
- Significant restructuring led to production now at highly competitive level, full capacity and top quality
- EBITDA and margins improved due to significantly higher operational efficiencies
- Order book at historically high level – examination and surgical glove capacity for 2021 completely booked out, booking for 2022 already advanced
- Surgical gloves: record output and sales in 2020



1) Q3'19 EBITDA adjusted for € 4m due to release of provision in Sempermed for Brazilian court case for tax liabilities

2) Reversal of impairment requirement recognised at the end of the second quarter, now amounting to EUR 86.2 million based on the foreign exchange average rates for 2020



Agenda

Key Highlights (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)


Outlook (p.21)

Appendix (p.24)



Revenue development

in € m




1) Semperform has been split into Semperséal and Semperform as of 1 Jan 2020
 Change of each segment / sector for FY 2020 vs FY 2019.



Top line growth translates into higher reported EBITDA: Medical Sector strong – Industrial Sector resilient

Margin strength against the corona impact

in € m




	FY 2019	Semperfex	Sempertrans	Semperséal	Semperform	Sempermed	Corporate	FY 2020
EBITDA FY 2019	67.8m	47.9m	13.5m	10.4m	15.6m	5.5m	-25.3m	
EBITDA FY 2020		41.9m	8.7m	11.0m	15.0m	150.4m	-18.4m	208.6m
EBITDA margin FY 2020	8.1%	22.1%	7.7%	11.8%	18.3%	33.5%	–	22.5%

Change of intercompany consolidation included in Corporate




Financials and profitability overview

EBITDA¹




- EBITDA margin, in %
- adjusted EBITDA margin, in %
- EBITDA, in € m
- adjusted EBITDA, in € m

EBIT¹



- EBIT margin, in %
- adjusted EBIT margin, in %
- EBIT, in € m
- adjusted EBIT, in € m

Earnings after tax



- Earnings after tax, in € m
- adjusted earnings after tax, in € m


¹⁾ FY 2019 adjusted for positive one-off effects of EUR 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of EUR 48.8m from impairment at Sempermed (adj. for EBIT and EAT).
 FY 2020 adjusted for the positive special effect from the write-up in the Sempermed segment (EBIT effect: EUR +86.2m; earnings after tax effect: EUR +88.8m) and the negative special effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8m; Earnings after taxes effect: EUR -16.1m)



Working Capital overview

Components of Working Capital

in € m



¹⁾ Trade Working Capital in % of LTM revenues




Free cash flow development and CAPEX

Cash Flow Development

- Further improved results, active WC management and strict CAPEX control
- FY 2020 FCF almost three times as high as FY 2019

CAPEX

- FY 2020 CAPEX at € 26.4m – main focus on maintenance
- Outlook 2021: planned to be twice as high as low benchmark in 2020



¹⁾ 2017 investment cash flow adjusted by € 160m (Joint Venture Termination)


²⁾ Cashflow calculation methodology change as of end of 2018, 2017 adjusted accordingly: “interest received” is now shown under cash flow from investing activities instead of operating activities, “interest paid” is now included in cash flow from financing activities instead of operating activities.



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 31/12/2020: € 764m
Balance sheet 31/12/2019: € 702m



Financial profile as of 31 December 2020

- **Cash and cash equivalents** of € 145m
- **Corporate Schuldschein loan** partially repaid, currently at € 167m
- **Newly agreed more flexible undrawn Credit Facility of € 75m** to secure liquidity
- **Net debt down** at € 22.1m, Net debt / EBITDA of 0.1x
- **Equity ratio** of 43.5%
- **Hybrid repayment** of € 100m in H2'20, remaining € 30m to be paid back in March '21



Agenda

Key Highlights (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)

Outlook (p.21)

Appendix (p.24)



From restructuring to transformation: outlook and targets

Restructuring (2018-2020):

Industrial Sector – Resilient and well prepared for future growth

Medical Sector – strong focus on business execution with highly efficient operational set up

Sustainable cost reduction programme initiated



Transition (ongoing):

Guidance: € 395 mn EBITDA for 2021

Separation from Sempermed with clear strategic rationale (market prices, order book, market environment)



Transformation:

Comprehensive strategy project started to benefit from megatrends, enhance the geographical footprint, enlarge the industrial business exposure and emphasise both on digitalisation and ESG

Focus on strategic M&A





Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Modecenterstrasse 22

1031 Vienna, Austria

Financial Calendar 2021

27.04.2021	Annual general meeting, Vienna
03.05.2021	Dividend payment day
19.05.2021	Report on Q1 2021
19.08.2021	Half-year financial report 2021
17.11.2021	Report on Q1-3 2021

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights (p.2)

Operational Highlights (p.6)

Financial Performance (p.14)

Outlook (p.21)

Appendix (p.24)



Sectors and Group: FY 2020 vs FY 2019

in EUR m	Industrial Sector ¹⁾			Medical Sector ²⁾			Semperit Group ³⁾		
	FY 2020	FY 2019	%	FY 2020	FY 2019	%	FY 2020	FY 2019	%
Revenue	478.4	547.2	-12.6%	449.2	293.3	53.1%	927.6	840.6	+10.4%
EBITDA	76.6	87.5	-12.4%	150.4	5.5	>100%	208.6	67.8	>100%
EBITDA margin	16.0%	16.0%	+0.0 PP	33.5%	1.9%	+31.6 PP	22.5%	8.1%	+14.4 PP
Adj. EBITDA	76.6	87.5	-12.4%	150.4	1.4	>100%	208.6	63.8	>100%
Adj. EBITDA margin	16.0%	16.0%	+0.0 PP	33.5%	0.5%	+33.0 PP	22.5%	7.6%	+14.9 PP
EBIT	32.4	60.9	-46.7%	224.9	-50.2	>100%	237.8	-16.5	>100%
EBIT margin	6.8%	11.1%	-4.3 PP	50.1%	-17.1%	+67.2 PP	25.6%	-2.0%	+27.6 PP
Adj. EBIT	52.2	60.9	-14.2%	138.7	-5.5	>100%	171.4	28.2	>100%
Adj. EBIT margin	10.9%	11.1%	-0.2 PP	30.9%	-1.9%	+32.8 PP	18.5%	3.4%	+15.1 PP
Earnings after tax	-	-	-	-	-	-	194.6	-44.9	>100%
Adj. Earnings after tax	-	-	-	-	-	-	121.9	-0.2	>100%
Earnings per share in EUR	-	-	-	-	-	-	9.06	-2.50	>100%
Additions in tangible and intangible assets	22.5	22.7	-1.1%	5.0	8.0	-37.9%	28.5	31.4	-9.2%
Employees	3,465	3,601	-3.8%	3,337	3,165	+5.4%	6,943	6,902	+0.6%

¹⁾ 2020: adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT: EUR -19.8 million)

²⁾ 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million), 2019 adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR +4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: EUR -48.8 million)


³⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million), 2019 adjusted for the positive one-off effect from the reversal of a provision for the tax proceedings on levies in Brazil (EBITDA, EBIT and earnings after taxes: EUR 4.0 million), as well as the negative effect of the impairment loss at Sempermed (EBIT and earnings after tax: EUR -48.8 million) for the segment




Semperit Group adj. where applicable

Semperit Group adj. where applicable																
in EUR m	FY 2017 adj. ¹⁾	Q1 2018	Q2 2018 adj. ²⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. ³⁾	Q4 2019 adj. ⁴⁾	FY 2019	Q1 2020	Q2 2020 adj. ⁵⁾	Q3 2020 adj. ⁶⁾	Q4 2020 adj.	FY 2020 adj. ⁷⁾
Revenue	874.2	220.9	227.6	221.7	208.2	878.5	212.9	224.4	214.9	188.3	840.6	199.1	219.8	238.2	270.5	927.6
EBITDA	35.8	15.8	17.0	13.1	4.5	50.3	16.5	22.7	17.3	7.4	63.8	16.9	40.7	60.9	90.0	208.6
EBITDA margin	4.1%	7.1%	7.5%	5.9%	2.2%	5.7%	7.7%	10.1%	8.0%	3.9%	7.6%	8.5%	18.5%	25.6%	33.3%	22.5%
EBIT	-0.8	6.0	7.2	4.3	-2.2	15.4	7.8	13.1	8.1	-0.7	28.2	9.8	33.6	49.2	78.8	171.4
EBIT margin	-0.1%	2.7%	3.2%	1.9%	-1.0%	1.7%	3.7%	5.8%	3.8%	-0.4%	3.4%	4.9%	15.3%	20.7%	29.1%	18.5%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q1 2017 adj. for positive one-off effects from JV transaction of € 85m. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (€ 11m) and valuation adjustment in IT (€ 4m EBITDA), expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ²⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA). ³⁾ Q3 2019 adjusted for negative one-off effect of € 47m from impairment of Sempermed (adj. for EBIT) and € 4m (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities. ⁴⁾ Q4 2019: impairment figure of Q3 2019 stepped up by € 2m due to additions to assets and FY deviations ⁵⁾ Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect -20.0 Million EUR) ⁶⁾ Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR -2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). ⁷⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million)



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)																
	FY 2017 adj. ¹⁾	Q1 2018	Q2 2018	Q3 2018 adj. ²⁾	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020
in EUR m																
Revenue	206.1	58.8	62.8	53.4	55.1	230.0	61.1	59.7	53.8	48.0	222.7	46.8	51.5	46.6	45.0	189.9
EBITDA	41.4	13.7	14.9	9.3	10.9	48.9	13.9	14.5	10.8	8.7	47.9	9.3	14.0	11.4	7.2	41.9
EBITDA margin	20.1%	23.4%	23.8%	17.4%	19.8%	21.3%	22.8%	24.3%	20.0%	18.1%	21.5%	19.9%	27.2%	24.5%	16.0%	22.1%
EBIT	32.7	11.1	12.3	6.9	8.1	38.4	11.1	11.5	7.8	5.7	36.0	6.5	11.2	8.7	4.5	30.9
EBIT margin	15.9%	18.9%	19.7%	12.9%	14.8%	16.7%	18.2%	19.2%	14.2%	11.9%	16.2%	13.9%	21.8%	18.6%	10.0%	16.3%

Sempertrans (Conveyor belts)																
	FY 2017 adj. ¹⁾	Q1 2018	Q2 2018 adj. ²⁾	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 adj. ⁵⁾	FY 2020 adj. ⁶⁾
in EUR m																
Revenue	146.0	34.6	37.0	37.6	35.5	144.8	30.4	37.8	35.1	30.6	134.0	29.5	32.5	28.4	22.7	113.1
EBITDA	-5.3	0.5	0.8	2.4	0.7	4.4	2.7	5.4	4.6	0.8	13.5	1.6	5.0	2.1	0.0	8.7
EBITDA margin	-3.6%	1.4%	2.1%	6.4%	2.1%	3.0%	9.0%	14.2%	13.1%	2.5%	10.1%	5.4%	15.4%	7.6%	0.0%	7.7%
EBIT	-8.9	-0.4	-0.1	1.6	-0.4	0.7	1.8	3.8	3.6	-0.3	8.9	0.6	3.9	1.4	-1.0	4.9
EBIT margin	-6.1%	-1.1%	-0.2%	4.3%	-1.1%	0.5%	6.0%	10.0%	10.4%	-0.9%	6.7%	1.9%	11.9%	5.0%	-4.4%	4.3%

¹⁾ Q1 2017 adj. for positive one-off effects from JV transaction of EUR 85 million. Figures for Q2, Q3 and Q4 2017 restructuring expenses/closure in France (EUR 11 million) and valuation adjustment in IT (EUR 4 million EBITDA), expenses resulting from tax audit in Austria (EUR 5 million, mainly for refund of energy supply charge).

²⁾ Q2 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (EUR 4 million for EBITDA).

³⁾ Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempermed segment (EBIT effect: EUR 20.0 million).

⁴⁾ Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

⁵⁾ Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

⁶⁾ 2020 Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)



Semperform and Semperséal (adj. where applicable)

Semperform (Window and door profiles, Handrails) - before 2020

in EUR m	Q1 2017	Q2 2017	Q3 2017 adj. ¹⁾	Q4 2017	FY 2017 adj. ¹⁾	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
Revenue	45.3	50.1	46.9	42.7	185.0	47.5	50.7	50.3	43.7	192.2	49.9	50.5	47.8	42.4	190.6
EBITDA	5.0	7.8	5.2	3.6	21.5	4.5	7.3	6.2	3.9	21.9	7.9	8.3	6.6	3.3	26.0
EBITDA margin	10.9%	15.5%	11.0%	8.5%	11.6%	9.6%	14.4%	12.2%	8.9%	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%
EBIT	3.0	5.8	3.2	1.3	13.3	2.4	5.1	4.2	1.5	13.2	5.4	5.9	4.2	0.5	16.0
EBIT margin	6.6%	11.5%	6.8%	3.0%	7.2%	5.0%	10.1%	8.4%	3.4%	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%

Semperform (Window and door profiles, Handrails) - after 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020
Revenue	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4	19.6	81.8
EBITDA	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0	2.5	15.0
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%	12.9%	18.3%
EBIT	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1	1.6	11.3
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%	8.0%	13.8%

Semperséal (Profiles and Rubber Sheeting) starting in 2020

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020
Revenue	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4	22.2	93.6
EBITDA	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9	1.7	11.0
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%	7.5%	11.8%
EBIT	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4	0.2	5.1
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%	1.1%	5.5%

Split of former Semperform into Semperséal and Semperform as of 1st January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly



Sempermed (adj. where applicable)

Sempermed (Gloves)																
	FY 2017 adj. ^{1) 2)}	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019 adj. ³⁾	Q4 2019	FY 2019 ⁴⁾	Q1 2020	Q2 2020 adj. ⁵⁾	Q3 2020 adj. ⁶⁾	Q4 2020 adj. ⁷⁾	FY 2020 adj. ⁸⁾
in EUR m																
Revenue	337.1	80.0	77.1	80.4	73.9	311.5	71.5	76.4	78.2	67.3	293.3	77.5	92.2	118.4	161.0	449.2
EBITDA	1.8	1.4	-1.3	-0.9	-3.1	-3.9	-0.9	0.6	1.8	-0.1	1.4	4.8	18.2	44.4	83.0	150.4
EBITDA margin	0.5%	1.8%	-1.7%	-1.1%	-4.2%	-1.3%	-1.2%	0.8%	2.3%	-0.1%	0.5%	6.1%	19.7%	37.5%	51.6%	33.5%
EBIT	-12.1	-2.2	-5.1	-3.9	-3.1	-14.3	-2.8	-1.4	-0.3	-0.9	-5.5	4.3	17.6	38.9	77.8	138.7
EBIT margin	-3.6%	-2.8%	-6.6%	-4.8%	-4.2%	-4.6%	-3.9%	-1.9%	-0.4%	-1.4%	-1.9%	5.5%	19.1%	32.8%	48.3%	30.9%

¹⁾ Adj. for expenses resulting from tax audit in Austria, mainly for refund of energy supply charge (EUR 2 million for Sempermed, EUR 2 million for Sempermed)

²⁾ Q3 2017 Sempermed adj. for positive one-off effects from JV transaction of EUR 78 million for EBITDA.

³⁾ Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

⁴⁾ 2019 adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR))

⁵⁾ Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

⁶⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

⁷⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

⁸⁾ 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)



Key figures 2010-2020

Key performance figures											
in EUR m	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ⁴⁾	2015 ⁴⁾	2016 adj. ⁴⁾	2017 adj. ⁴⁾	2018 adj. ⁵⁾	2019 adj. ⁶⁾	2020 adj. ⁷⁾
Revenue	689.4	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6	927.6
EBITDA	112.3	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6
EBITDA margin	16.3%	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%
EBIT	82.3	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4
EBIT margin	11.9%	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.4%	18.5%
Earnings after tax	45.4	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2	121.9
Gross cash flow	91.0	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.70	193.7
Return on equity	12.9%	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%

Balance sheet key figures											
in EUR m	2010 ¹⁾	2011 ¹⁾	2012	2013	2014 ⁴⁾	2015 ⁴⁾	2016	2017	2018	2019	2020
Balance sheet total	593.5	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4
Equity	351.1	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	273.4	332.3
Equity ratio	59.2%	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%
Investments in tangible and intangible assets (CAPEX)	52.5	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4
Employees, at balance sheet date, FTEs	7,019	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943


¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18), 2010 not restated. ²⁾ 2014 and 2015 restated. ³⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ⁴⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ⁵⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only). ⁶⁾ FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁷⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million)



CAPEX by quarter

CAPEX per segment


in € m





Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0




Overview price indices LFO-F-NWE / wire rod

Significant increase for raw material¹⁾ used in industrial segments

Price index LFO-F-NWE



Price index wire rod



¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment overview, FY 2020

Semperit Group

Group	Industrial Sector				Medical Sector	
	Semperflex	Sempertrans	Semperform ⁴⁾	Semperseal ⁴⁾	Sempermed	
Revenue	927.6	189.9 / 20% ¹⁾	113.1 / 12% ¹⁾	81.8 / 9% ¹⁾	93.6 / 10% ¹⁾	449.2 / 48% ¹⁾
EBITDA	208.6 ²⁾	41.9	8.7	15.0	11.0	150.4
Employees	6,943 ²⁾	1,571 / 23% ³⁾	917 / 13% ³⁾	520 / 7% ³⁾	457 / 7% ³⁾	3,337 / 48% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe



Conveyor belts

One of the leading providers for heavyduty steel and textile cord belts



Profiles / Handrails

Leading European manufacturers of moulded and extrusion products made of rubber and plastic (handrails, cable car rings, ski foils and Engineered Solutions)



Profiles / Sheeting

Leading European manufacturer of sealing profiles and rubber sheeting (profiles for windows, doors & facades, wear-resistant protective sheeting)



Examination gloves

Among the top 10 glovemakers in the world



Surgical gloves

Leading position in Europe



¹⁾ Revenue in % of Group revenue.

²⁾ Group figure includes corporate center of € -18m, 136 employees.

³⁾ Employees in % of Group employees.


⁴⁾ The business units Profiles and Rubber

Sheeting were separated from the Semperform segment and are operated as individual segments under the name Semperseal as of 1 January 2020.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C